第 1 到 32 筆結果,共 32 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer | YEN-TING LIN ; CHAO-CHI HO ; Hsu, Wei-Hsun; WEI-YU LIAO ; CHING-YAO YANG ; CHONG-JEN YU ; TZU-HSIU TSAI ; CHIH-HSIN YANG ; SHANG-GIN WU ; CHIA-LIN HSU ; Hsieh, Min-Shu; YEN-LIN HUANG ; Wu, Chia-Ling; JIN-YUAN SHIH | Cancer medicine | 0 | ||
2 | 2023 | Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system | CHING-YAO YANG ; JIN-YUAN SHIH ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; TZU-HSIU TSAI ; SHANG-GIN WU ; YEN-TING LIN ; Hsu, Wei-Hsun; Jain, Suyog; Olsen, Steve; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | European journal of cancer (Oxford, England : 1990) | 0 | 0 | |
3 | 2023 | Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients | SHENG-KAI LIANG ; Wu, Chang-Wei; Chang, Ching-I; LI-TA KENG ; MENG-RUI LEE ; JANN-YUAN WANG ; JEN-CHUNG KO ; WEI-YU LIAO ; KUAN-YU CHEN ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU | Cancer medicine | 0 | 0 | |
4 | 2023 | Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors | CHUN-TA HUANG ; Lin, Chih-An; Su, Te-Jen; CHING-YAO YANG ; TZU-HSIU TSAI ; CHIA-LIN HSU ; WEI-YU LIAO ; KUAN-YU CHEN ; CHAO-CHI HO ; CHONG-JEN YU | BMC cancer | 5 | 2 | |
5 | 2022 | Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma | CHIA-LING CHANG ; MIN-SHU HSIEH ; JIN-YUAN SHIH ; Lee, Yi-Hsuan; WEI-YU LIAO ; CHIA-LIN HSU ; CHING-YAO YANG ; KUAN-YU CHEN ; JIH-HSIANG LEE ; CHAO-CHI HO ; TZU-HSIU TSAI ; CHIH-HSIN YANG ; CHONG-JEN YU | Therapeutic advances in medical oncology | 1 | 1 | |
6 | 2021 | Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer | CHIA-LIN HSU ; TZU-HSIU TSAI ; CHUN-KAI HUANG ; CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; SHENG-YUAN RUAN ; KUAN-YU CHEN ; JIN-YUAN SHIH ; PAN-CHYR YANG | Lung cancer (Amsterdam, Netherlands) | 5 | 5 | |
7 | 2021 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC | BIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG | JTO clinical and research reports | 2 | 0 | |
8 | 2021 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study | Huang, Yen-Hsiang; Hung, Jen-Yu; Ko, How-Wen; Su, Po-Lan; Lai, Chun-Liang; Chang, Huang-Chih; Hsia, Te-Chun; Lin, Sheng-Hao; Wu, Kuan-Li; Yang, Cheng-Ta; Su, Wu-Chou; Chu, Yi-Chun; Wang, Chin-Chou; WEI-YU LIAO ; YEN-TING LIN ; Lin, Ching-Hsiung; Lin, Meng-Chih; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Lee, Mei-Hsuan; SUNG-LIANG YU ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 3 | 2 | |
9 | 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 55 | 49 | |
10 | 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 15 | 15 | |
11 | 2019 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations | YEN-TING LIN ; JIN-SHING CHEN ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; Yang C.-Y.; KUAN-YU CHEN ; JIH-HSIANG LEE ; ZHONG-ZHE LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | International Journal of Cancer | 53 | 46 | |
12 | 2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
13 | 2018 | Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study | SHENG-KAI LIANG ; MENG-RUI LEE ; WEI-YU LIAO ; CHAO-CHI HO ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 17 | 0 | |
14 | 2018 | The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer | KAI-LUN YU ; TZU-HSIU TSAI ; CHAO-CHI HO ; WEI-YU LIAO ; CHING-KAI LIN ; CHIA-LIN HSU ; JIN-YUAN SHIH | Scientific Reports | 12 | 10 | |
15 | 2018 | Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan | SHU-YUNG LIN ; Yang C.-Y.; BIN-CHI LIAO ; CHAO-CHI HO ; WEI-YU LIAO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Hsu W.-H.; KANG-YI SU ; YIH-LEONG CHANG ; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Journal of Cancer | 40 | 41 | |
16 | 2018 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 120 | 109 | |
17 | 2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 16 | 17 | |
18 | 2018 | Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum | WEI-YU LIAO ; CHAO-CHI HO ; TZU-HSIU TSAI ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU | Lung Cancer | 14 | 11 | |
19 | 2018 | Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery | WEN-CHI YANG ; FU-REN XIAO ; JIN-YUAN SHIH ; CHAO-CHI HO ; YA-FANG CHEN ; Tseng H.-M.; KUAN-YU CHEN ; WEI-YU LIAO ; CHONG-JEN YU ; CHIH-HSIN YANG ; SUNG-HSIN KUO ; CHIA-HSIEN CHENG ; PAN-CHYR YANG ; FENG-MING HSU | Radiotherapy and Oncology | 22 | 21 | |
20 | 2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
21 | 2017 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | CHAO-CHI HO ; WEI-YU LIAO ; Lin C.-A.; JIN-YUAN SHIH ; CHONG-JEN YU ; Chih-Hsin CHIH-HSIN YANG | Journal of Thoracic Oncology | 179 | 164 | |
22 | 2016 | Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases | Lin C.-H.; SONG-CHOU HSIEH ; LI-TA KENG ; Lee H.-S.; Chang H.-T.; WEI-YU LIAO ; CHAO-CHI HO ; CHONG-JEN YU | PLoS ONE | 6 | 5 | |
23 | 2016 | Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis | Chen L.-Y.; Molina-Vila M.A ; SHENG-YUAN RUAN ; KANG-YI SU ; WEI-YU LIAO ; KAI-LUN YU ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; Rosell R.; PAN-CHYR YANG | Lung Cancer | 57 | 52 | |
24 | 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 13 | 12 | |
25 | 2015 | Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan | Hsu K.-H.; CHAO-CHI HO ; Hsia T.-C.; Tseng J.-S.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Chang G.-C. | PLoS ONE | 98 | 92 | |
26 | 2015 | Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer | WEI-YU LIAO ; CHAO-CHI HO ; HSIN-HAN HOU ; Hsu T.-H.; Tsai M.-F.; KUAN-YU CHEN ; Chen H.-Y.; Lee Y.-C.; CHONG-JEN YU ; Lee C.-H.; PAN-CHYR YANG | Journal of Pathology | 23 | 20 | |
27 | 2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
28 | 2013 | Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer | WEI-YU LIAO ; Chen J.-H.; Wu M.; JIN-YUAN SHIH ; KUAN-YU CHEN ; CHAO-CHI HO ; CHIH-HSIN YANG ; CHONG-JEN YU | Clinical Lung Cancer | 22 | 20 | |
29 | 2013 | Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy | TZU-HSIU TSAI ; CHING-YAO YANG ; CHAO-CHI HO ; WEI-YU LIAO ; I-SHIOW JAN ; KUAN-YU CHEN ; JANN-YUAN WANG ; SHENG-YUAN RUAN ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG ; JIN-YUAN SHIH | Lung Cancer | 33 | 30 | |
30 | 2012 | Risk Factors of Pneumothorax after Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Lung Lesions | CHUN-TA HUANG ; SHENG-YUAN RUAN ; WEI-YU LIAO ; YAO-WEN KUO ; Lin C.-Y.; Tsai Y.-J.; CHAO-CHI HO ; CHONG-JEN YU | PLoS ONE | 26 | 25 | |
31 | 2012 | Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: How many specimens are necessary? | CHUN-TA HUANG ; Tsai Y.-J.; WEI-YU LIAO ; Wu P.-C.; CHAO-CHI HO ; CHONG-JEN YU ; PAN-CHYR YANG | Respiration | 21 | 21 | |
32 | 2008 | TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer | CHAO-CHI HO ; WEI-YU LIAO ; Wang C.-Y.; Lu Y.-H.; Huang H.-Y.; Chen H.-Y.; Chan W.-K.; HUEI-WEN CHEN ; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 117 | 110 |